Article | Pharma Marketer

Cytori gains European OK for stem cell tech

Tuesday, July 27th, 2010

Shares of Cytori Therapeutics ( CYTX ) were buoyed by the news that European regulators have approved its stem cell technology for a range of procedures including breast reconstruction surgery and tissue repair.

Posted in: Pharma News | 0 Comments »

Read the full story

DMC: Novartis’ drug safe but not effective in mid-study analysis

Friday, July 23rd, 2010

An independent data monitoring committee (DMC) has

Posted in: Pharma News | 0 Comments »

Read the full story

Cancer Vaccines: Northwest Biotherapeutics vs. Dendreon

Friday, July 16th, 2010

M.E. Garza submits: As a followup to our interview with Northwest Biotherapeutics’ ( NWBO.OB ) Chairman of the Board of Linda Powers, this article focuses on the “hard differentiators” between NWBO’s immunotherapy vaccine platform and that of their closest competitor Dendreon Corporation ( DNDN )

Posted in: Pharma News | 0 Comments »

Read the full story

An Avandia Study Author…Or So We Thought?

Tuesday, July 13th, 2010

Steve Haffner played a relatively modest role in the Avandia scandal, but until now, he was known primarily for leaking to GlaxoSmithkline the damaging meta-analysis of the diabetes pill that was published in The New England Journal of Medicine three years ago. Haffner later acknowledged breaching his responsibility as a peer reviewer, but blamed “bad judgment” because he wasn’t “feeling well.” In doing so, Glaxo was able to respond very quickly to the disclosure ( back story ). As it happens, Haffner felt just fine several years earlier when he allegedly had an Avandia study ghostwritten for him

Posted in: Pharma News | 0 Comments »

Read the full story

Hmmm: The Gates Foundation Bails

Tuesday, July 13th, 2010

According to this piece , the Gates Foundation unloaded basically all of its pharma and biotech stock holdings during the second quarter. Merck/Schering-Plough, J&J, Lilly, through Vertex and all the way to InterMune, Allos, and Auxilium – they held millions of shares of these, and it’s all gone. I presume that this is some sort of sector-rotation move by the foundation’s investment advisors

Posted in: Clinical Trials | 0 Comments »

Read the full story

Monoclonal Antibody Companies Command Premiums

Monday, July 12th, 2010

Michael Becker submits: Monoclonal antibodies, which have been approved for immunological, anti-infective, ophthalmic, cancer and other categories, represent one of the most successful therapeutic drug classes. Ten monoclonal antibodies have been approved for cancer therapy alone, including three blockbuster products sold by the Roche Group ( RHHBY.PK ) – Avastin

Posted in: Biotechnology, Clinical Trials, Pharma News, Technology | 0 Comments »

Read the full story

Is the entire system corrupt to the extent that we can’t trust the data ?

Saturday, July 10th, 2010

In an interview on Friday, Dr. Jerome P. Kassirer, a former editor of The New England Journal, said the Record trial raised the question “whether the entire system is corrupt.” “To the extent that we can’t trust the data,” he added, “we are in jeopardy of giving patients the wrong drugs.” And how does GSK respond to this report ?

Posted in: DTC | 0 Comments »

Read the full story

Is the entire system is corrupt to the extent that we can’t trust the data ?

Saturday, July 10th, 2010

In an interview on Friday, Dr. Jerome P. Kassirer, a former editor of The New England Journal, said the Record trial raised the question “whether the entire system is corrupt.” “To the extent that we can’t trust the data,” he added, “we are in jeopardy of giving patients the wrong drugs.” And how does GSK respond to this report ?

Posted in: DTC | 0 Comments »

Read the full story

Excelimmune garners $4.5M in new financing

Wednesday, July 7th, 2010

Woburn, MA-based Excelimmune has rounded up $4.5 million in new financing for its planned clinical development work on polyclonal antibodies. The financing–roughly half of the $8.9 million the developer is seeking–was

Posted in: Pharma News | 0 Comments »

Read the full story

The Winner of ASCO 2010: Bristol Myers Squibb

Sunday, July 4th, 2010

Ohad Hammer submits: The hottest theme at this year’s 2010 ASCO (American Society of Clinical Oncology) annual meeting was without a doubt cancer immunotherapy , an old paradigm that deals with redirecting the patient’s immune system against tumors. After decades of failures, this concept is finally proving itself useful.

Posted in: Pharma News | 0 Comments »

Read the full story